Paul Thomen

Wednesday, 27 February 2013

Fuel Injection Systems Market By Technology, Engine Type, Geography Forecast to 2018

Fuel injection system is a vital component in any automotive engine. With continuous developments occurring in gasoline and diesel injection technologies, various automobile manufacturers have succeeded in meeting stringent carbon emission norms and improving fuel economy of vehicles. A typical fuel injection system is an assembly of number of components governed by electronic control unit (ECU) which regulates and monitors the quantity of fuel entering into engine cylinders depending upon engine requirements.

A fuel injection system does not only supply fuel for combustion process but also decides on how a particular system would be optimized. Modern fuel injection systems are responsible for injection timing, atomization, and injection quality. They also provide several additional functions which include rate shaping (or scheduling the injection of fuel), multiple injections, pilot injection, and post injection. The components such as fuel injectors, electronic control unit (ECU), fuel pressure regulators, fuel pumps etc. are vital in the proper functioning of a fuel injection system.

The report segments the market based on vehicle types (passenger, commercial, heavy trucks and buses, and two-wheelers); geography (Asia-Pacific, Europe, North America, and Rest of the World); engine types (gasoline, diesel); technology (gasoline direct injection, port injection, and diesel direct injection); components (injectors, ECU, pressure regulators, high pressure pumps), and provides market forecast in terms of volume (number of fuel injection systems) and revenue ($million) for aforesaid segments.

The report classifies and defines the demand for fuel injection systems in the automobile industry. It covers qualitative data about fuel injection as a system, its components and functions. The report also provides a comprehensive review of major market drivers, restraints, opportunities, challenges, and key issues in the fuel injection system market. The major players in fuel injection systems market are Bosch, Denso, Delphi and Continental AG.


Fuel injection technologies: Changing buyer’s preferences

The advancement in fuel injection technologies has led to many modifications in passenger car segment. For instance, with the development of diesel injection technology the automobile market saw a quick adoption of diesel engines in small passenger car segment. This led to growing preference of diesel cars across the globe.

Improved fuel efficiency & power output, reliability, basic diagnostic capability, ability to accommodate some of the alternative fuels, and decreased exhaust emissions are some of the factors that have primarily propelled the demand for fuel injection systems in automobile industry. Many of the two wheeler manufacturers across the globe are also focusing on the use of fuel injection technology in two-wheelers with less engine capacity (150cc and below). The overall demand of fuel injection system is expected to increase at a promising rate in the future. Hence, many technological developments pertaining to cost-effectiveness and efficiency of the fuel injection system can be expected in subsequent five years.

Scope of the Report

The fuel delivery and injection systems go hand in hand. The fuel delivery system supplies required amount of fuel to the injection system which in turn starts fuel ignition, combustion and resultant exhaust. However, the scope of the report covers fuel injection technology as a system.

The global fuel injection system market is analyzed in terms of volume (thousand units) and value ($million) for the aforesaid vehicle types, fuel types, and product types by regions and respective major countries.

By Geography
Asia-Pacific
Europe
North America
ROW

By Components
Fuel injectors
Electronic Control Unit (ECU)
Fuel Pressure Regulator (FPR)
High pressure fuel pump

By Vehicle Types
Passenger cars
Light commercial vehicles
Heavy trucks/buses/coaches
Two-Wheelers
Asia-Pacific
Europe
North America
ROW

By Engine Types
Gasoline/Petrol
Diesel

By Technology
Gasoline injection
Port or Multi-point fuel injection
Direct injection
Diesel injection
Direct injection

Buy a Report Copy @ http://www.rnrmarketresearch.com/contacts/purchase?rname=78420

Tuesday, 26 February 2013

Offshore Wind Power Market Size, Share and Key Country Analysis to 2020

Offshore Wind Power – Global Market Size, Average Installation Price, Regulations, Market Share and Key Country Analysis to 2020″ is a key alternative energy report from GlobalData, that offer comprehensive information and understanding of the global offshore wind power market. The research provides an understanding of the key drivers, restraints and trends in the global offshore wind market. It also provides historical and forecast data to 2020 for installed capacity and power generation. The report details the turbine market share and installed capacity by country. The report analyses offshore wind power market in key countries like the UK, Germany, Sweden, Denmark, Belgium, China and the US. The key country analysis include installed capacity, power generation, average installation price, market size, levelized cost of electricity (LCOE), market share, active and upcoming projects and major regulations.

The report is built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis by GlobalData’s Team of industry experts.

Scope

The report analyzes the global offshore wind power market and includes -
- Data on installed capacity, installed capacity split by country and market segmentation by onshore and offshore for global wind power market.
- Data on installed capacity, power generation, installed capacity split by country, turbine manufacturers share for the global offshore wind power market.
- Information on key drivers and restraints along with trends in offshore wind power market.
- Data on installed capacity, power generation, average installation price, market size, LCOE, market share, active and upcoming projects and major regulations for key countries like the UK, Germany, Sweden, Denmark, Belgium, China and the US.


Reasons to buy

The report will enhance your decision making capability. It will allow you to -
- Facilitate decision making based on strong historic and forecast data for the offshore wind power market.
- Develop strategies based on the latest regulatory events.
- Position yourself to maximize potential in the growth of the offshore wind power market.
- Identify key partners and business development avenues.
- Respond to your competitors’ business structure, strategy and prospects.

Buy a Report Copy @ http://www.rnrmarketresearch.com/contacts/purchase?rname=77464

Monday, 25 February 2013

Sweden and Austria Ophthalmic Devices Market 2018

GlobalData’s new report, “Sweden and Austria Ophthalmic devices Market Outlook to 2018 – Vision Care, Intraocular Lens (IOL), Cataract Surgery Devices, Ophthalmic Diagnostic Equipment, Refractive Surgery Devices, Vitreo Retinal Surgery Devices and Others” provides key market data on the Sweden and Austria Ophthalmic Devices market. The report provides value (USD million), volume (units) and average price (USD) data for each segment and sub-segment within seven market categories – Cataract Surgery Devices, Glaucoma Surgery Devices, Intraocular Lens (IOL), Ophthalmic Diagnostic Equipment, Refractive Surgery Devices, Vision Care and Vitreo Retinal Surgery Devices. The report also provides company shares and distribution shares data for each of the aforementioned market categories. The report is supplemented with global corporate-level profiles of the key market participants with information on company financials and pipeline products, wherever available.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

Scope

- Market size and company share data for Ophthalmic Devices market categories – Cataract Surgery Devices, Glaucoma Surgery Devices, Intraocular Lens (IOL), Ophthalmic Diagnostic Equipment, Refractive Surgery Devices, Vision Care and Vitreo Retinal Surgery Devices.
- Annualized market revenues (USD million), volume (units) and average price (USD) data for each of the segments and sub-segments within seven market categories. Data from 2004 to 2011, forecast forward for 7 years to 2018.
- 2011 company shares and distribution shares data for each of the seven market categories.
- Global corporate-level profiles of key companies operating within the Sweden and Austria Ophthalmic Devicesmarket.
- Key players covered include Essilor International, Johnson & Johnson Vision Care, Inc., Carl Zeiss AG, CooperVision, Inc., CIBA Vision Corporation, Bausch & Lomb Incorporated and others.

Request a Sample of Sweden Ophthalmic Devices Market Outlook to 2018 @ http://www.rnrmarketresearch.com/contacts/request-sample?rname=77628

Request a Sample of Austria Ophthalmic Devices Market Outlook to 2018 @ http://www.rnrmarketresearch.com/contacts/request-sample?rname=77625

Reasons to buy

- Develop business strategies by identifying the key market categories and segments poised for strong growth.
- Develop market-entry and market expansion strategies.
- Design competition strategies by identifying who-stands-where in the Sweden and Austria Ophthalmic Devices competitive landscape.
- Develop capital investment strategies by identifying the key market segments expected to register strong growth in the near future.
- What are the key distribution channels and what’s the most preferred mode of product distribution – Identify, understand and capitalize.

Friday, 22 February 2013

Intraocular Lens Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2018

GlobalData’s new report, “Intraocular Lens Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2018″ provides key market data on the Intraocular Lens (IOL) market in the BRICS countries. The report provides value ($m), volume (units) and average price ($) data for each segment within two market categories -Foldable IOL and Polymethyl Methacrylate (PMMA) IOL. The report also provides company shares and distribution shares data for the overall Intraocular Lens (IOL) market in each of the aforementioned countries. The report is also supplemented with global corporate-level profiles of the key market participants with information on key developments, wherever available.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

The emerging economies, comprising China, India, Brazil, Russia and South Africa, with a significantly large pool of under-served patients, represent the next big opportunity for the leading medical equipment and devices manufacturers. China remains the world’s most populous country and is consequently home to a large patient base. The country is home to more than 120 million people who are aged 65 or older—a population in continuous need of medical care. India, the second most populous country globally, is home to 1.2 billion people, approximately 5% of which are aged 65 or older. It’s estimated that shortly after 2020, India’s population will surpass China, making it the most populous country in the world. As the population continues to grow and people continue to age, the underlying demand for healthcare is also expected to increase.


Scope

- Market size data for Intraocular Lens (IOL) market categories – Foldable IOL and Polymethyl Methacrylate (PMMA) IOL.
- Annualized market revenues ($m), volume (units) and average price ($) data for each of the segments within the two market categories. Data from 2004 to 2011, forecast forward for seven years to 2018.
- 2011 company shares and distribution shares data for the overall Intraocular Lens (IOL) market in each of the aforementioned countries.
- Global corporate-level profiles of key companies operating within the Intraocular Lens (IOL) market in BRICS.
- Key players covered include Alcon, Inc., Hoya Corporation, Abbott Medical Optics, Inc., Bausch & Lomb Incorporated, Appasamy Associates, Intra Ocular Care Pvt. Ltd., Carl Zeiss AG, All Pro Intraocular Lens Co.,Ltd and STAAR Surgical Company.

Reasons to buy

- Develop business strategies by identifying the key market categories and segments poised for strong growth.
- Develop market-entry and market expansion strategies.
- Design competition strategies by identifying who-stands-where in the Intraocular Lens (IOL) competitive landscape in BRICS.
- Develop capital investment strategies by identifying the key market segments expected to register strong growth in the near future.
- What are the key distribution channels and what’s the most preferred mode of product distribution – Identify, understand and capitalize.

Buy a Report Copy @ http://www.rnrmarketresearch.com/contacts/purchase?rname=77595

Thursday, 21 February 2013

Zoladex, Provenge, Xgeva, Zometa Prostate Cancer Market Analysis Forecast to 2022

PharmaPoint Drug Evaluation report, “Zoladex, Provenge, Xgeva, Zometa (Prostate Cancer) – Forecast and Market Analysis to 2022″. The recent approvals of second-line metastatic castration-resistant prostate cancer (mCRPC) therapies like J&J’s Zytiga (abiraterone acetate) and Medivation/Astellas’ Xtandi (enzalutamide) will drive strong market growth over the next decade. These safe and orally administered treatments will provide safety and convenience benefits over the current standard of care, chemotherapy with docetaxel, while prolonging the overall survival of patients with mCRPC. The December 12, 2012 FDA approval of Zytiga for the added indication of chemotherapy-na├»ve mCRPC marks the onset of a new treatment paradigm for the disease, in which chemotherapy is relegated to second-line therapy and beyond. For patients with earlier-stage prostate cancer, androgen deprivation therapy with LHRH agonists and first-generation antiandrogens remains the standard of care for suppressing testosterone levels and temporarily controlling the disease.


Novartis’ Zometa is a bisphosphonate indicated for the treatment of bone metastases in patients with CRPC, other solid tumors, and multiple myeloma. Its active ingredient, zoledronic acid, inhibits osteoclastic activity and induces apoptosis in osteoclasts, the cells responsible for bone resorption (Zometa Prescribing Information, 2012). This helps prevent the SREs that are a common symptom of bone metastases. Zometa has also been shown to inhibit the increase in osteoclast activity resulting from various stimulatory factors released by tumors. Although Zometa has been a blockbuster, worldwide patent expiries between 2012 and 2013 will open the door for generic competition and undoubtedly erode its sales (Novartis Annual Report, 2011).

Request a Sample Copy of Zometa Prostate Cancer @ http://www.rnrmarketresearch.com/contacts/request-sample?rname=77537


Prostate cancer frequently metastasizes to the bones, increasing the likelihood of skeletal fractures. Amgen’s Xgeva is a human Monoclonal Antibody (mAb) that binds to RANKL, a protein produced by osteoclasts involved in bone resorption, and prevents it from activating its receptor, RANK, on the osteoclast surface. This prevents the osteoclasts from breaking down bone and causing SREs (Xgeva Prescribing Information, 2010).

Request a Sample Copy of Xgeva Prostate Cancer @ http://www.rnrmarketresearch.com/contacts/request-sample?rname=77535


Dendreon’s Provenge is the first FDA-approved therapeutic cancer vaccine, and is a treatment for mCRPC. It consists of the patient’s own immune cells, which have been activated against Prostatic Acid Phosphatase (PAP), a protein found in prostate cancer cells (Provenge Prescribing Information, 2011). These activated immune cells are then infused back into the patient and induce an immune response against the prostate cancer cells.

Request a Sample Copy of Provenge Prostate Cancer @ http://www.rnrmarketresearch.com/contacts/request-sample?rname=77529


AstraZeneca’s Zoladex is a subcutaneous implant that delivers goserelin acetate, a synthetic analog of LHRH. It is classified as an LHRH receptor agonist (Zoladex Prescribing Information, 2010). It binds to the LHRH receptor and prevents the pituitary gland from secreting luteinizing hormone. Without luteinizing hormone, the testes do not produce testosterone. Since testosterone is known to drive the progression of prostate cancer, LHRH analogs are commonly used in ADT regimens. Zoladex is commonly used to control hormone-sensitive prostate cancer, and to maintain castrate levels of testosterone in patients with CRPC.

Request a Sample Copy of Zoladex Prostate Cancer @ http://www.rnrmarketresearch.com/contacts/request-sample?rname=77518

Scope

- Overview of Prostate cancer, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Xgeva including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Xgeva for the top nine countries from 2012 to 2022.
- Sales information covered for the US, Japan, UK, France, Germany, Spain, Italy , Canada, and Australia

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for Prostate cancer
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of Xgeva performance
- Obtain sales forecast for Xgeva from 2012-2022 in nine markets (US, Japan, UK, France, Germany, Spain, Italy , Canada, and Australia)